about
Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir.Dynamic of Mixed HCV Infection in Plasma and PBMC of HIV/HCV Patients Under Treatment With Peg-IFN/Ribavirin.Frequency of Natural Resistance within NS5a Replication Complex Domain in Hepatitis C Genotypes 1a, 1b: Possible Implication of Subtype-Specific Resistance Selection in Multiple Direct Acting Antivirals Drugs Combination Treatment.Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patients.Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfected patients.NS3 protease resistance-associated substitutions in liver tissue and plasma samples from patients infected by hepatitis C virus genotype 1A or 1B.Dynamic change in the NS3 protease domain in HIV/HCV-coinfected patients naïve to anti-HCV protease inhibitors.Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis.TM6SF2 E167K variant predicts severe liver fibrosis for human immunodeficiency/hepatitis C virus co-infected patients, and severe steatosis only for a non-3 hepatitis C virus genotype.Diagnostic accuracy of APRI, FIB-4 and Forns for the detection of liver cirrhosis in HIV/HCV-coinfected patients.Impact of PNPLA3 variants on liver histology of 168 patients with HIV infection and chronic hepatitis C.Distribution of natural resistance to NS3 protease inhibitors in hepatitis C genotype 1a separated into clades 1 and 2 and in genotype 1b of HIV-infected patients.Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman.Systemic Inflammatory Response Is a Prognostic Marker in HIV-Infected Patients with Hepatocellular Carcinoma.Non-invasive fibrosis biomarkers - APRI and Forns - are associated with liver stiffness in HIV-monoinfected patients receiving antiretroviral drugs.Reversion of naturally occurring high-level resistance mutations to NS3 protease inhibitors in two treatment-naive individuals infected with hepatitis C virus.Marked Decrease in Lymphocyte Count in HIV/Hepatitis C Virus (HCV)-Coinfected Patients With Advanced Liver Disease During Anti-HCV Treatment With Direct-Acting Antiviral Regimens Including Ribavirin.Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients.The albumin-bilirubin grade uncovers the prognostic relationship between hepatic reserve and immune dysfunction in HIV-associated hepatocellular carcinoma.Feasibility of all-oral anti-HCV treatment during DHAP chemotherapy and autologous stem cell transplantation for T-cell lymphoma.Hepatitis A Virus in men who have sex with men: Need for awareness and vaccination.Occurrence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antiviralsHIV-positive to HIV-positive liver transplantation: To be continuedIn vivo evidence that the cannabinoid receptor 2-63 RR variant is associated with the acquisition and/or expansion of HIV infectionSevere cholestatic hepatitis related to abacavir/lamivudine/dolutegravir antiretroviral treatment in a HIV-1 infected subjectThe impact of HIV infection and men who have sex with men status on hepatitis A infection: The experience of two tertiary centres in Northern Italy during the 2017 outbreak and in the 2009-2016 periodRisk factors for community-acquired bacterial meningitis: men who have sex with men (MSM) as a population at risk for meningococcal nasopharyngeal carriageSustained virological response with 16-week glecaprevir/pibrentasvir after failure to sofosbuvir/velpatasvir in post-transplant severe HCV recurrence in HIVReply to "Coronaviruses and immunosuppressed patients. The facts during the third epidemic"
P50
Q36988748-869B0DF1-1E79-403E-B4DE-2F3DD562648AQ37176312-5AD93FD5-A7F7-4E0C-AAD6-C314071AF2ECQ38888859-3FD26EA8-7DEB-4013-BE3B-22D59BF2EE63Q40099619-7E64B427-F7DE-4006-B917-691D911A74ABQ40113130-CD792CB6-806A-432B-B10E-DB690CA847F4Q40237283-D5760504-CB23-4840-842C-0DC2DA68F12DQ40377822-A210AD2F-0D0A-4004-BB5D-7B7832E281AEQ40401740-9DF335FD-2CEE-4212-B23B-2B4A9125B75EQ40482870-E9F47DF2-02C1-4331-922D-A10D663E112BQ40667760-4AC640DE-7272-4EE5-8737-A34882238B60Q40819897-26408414-6532-4E97-8C42-A997FB3B2BC0Q40856569-071272F3-A331-47DD-A6D1-E86F2270B980Q41634185-1D791839-1B2A-4F71-ADC9-BD476B793268Q41936049-26AD1766-54BC-4F07-84E0-81C02D694359Q42269060-302C8DF0-BA81-4E65-8E15-EF9A76D7354BQ42988991-2EF06466-BFE2-4C51-B43D-10C459828A5BQ45340126-6E7032D2-1914-4E04-B4AC-B1DC2A001A8FQ47164735-0272EC7B-085F-4B50-8B66-655177070EEEQ47611543-F555DF59-7B83-47C4-9B47-492F7A8F3E4FQ52604889-EB32EB59-9508-415E-B0D4-941916B5E312Q54249030-E0DFDE6B-F002-4E7F-9658-F1F2645DA671Q58290221-0DD13966-1BAE-4911-BC3A-27DAF1906A2EQ59355935-A1CD0B96-97F7-46D5-9FF9-73D5005EEDB7Q60232509-1C2F5C82-2954-436D-B73F-AAC8C3BB6573Q89997364-FB334EC7-42FB-49D9-A8C7-46C94ED0BF3FQ91885445-27F53F23-2BEC-4DA0-8121-E8D3B5CDCC2EQ92064758-8C8D5682-DAA8-4A23-B520-18204EEE9F98Q93121026-6B96CDBC-38FF-45C2-8E6C-F4B79E911389Q96016599-99FEBC59-A6C8-4F54-8084-50FBDB5FB2BE
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Marco Merli
@ast
Marco Merli
@en
Marco Merli
@es
Marco Merli
@fr
Marco Merli
@nl
Marco Merli
@sl
type
label
Marco Merli
@ast
Marco Merli
@en
Marco Merli
@es
Marco Merli
@fr
Marco Merli
@nl
Marco Merli
@sl
prefLabel
Marco Merli
@ast
Marco Merli
@en
Marco Merli
@es
Marco Merli
@fr
Marco Merli
@nl
Marco Merli
@sl
P106
P21
P31
P496
0000-0001-5081-8669